Molecular monitoring of Plasmodium falciparum resistance to artemisinin in Tanzania

Malaria Journal

Volumn 5, Issue , 2006, Pages

  Mugittu, Kefas ^a,b   Genton, Blaise ^a,b   Mshinda, Hassan ^a   Beck, Hans Peter ^b  

^a IFAKARA HEALTH INSTITUTE   (Tanzania)

^b SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ARTEMETHER PLUS BENFLUMETOL; ARTEMISININ;

ARTICLE; CONTROLLED STUDY; DNA MICROARRAY; DRUG MECHANISM; ENZYME INHIBITION; GENE MUTATION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALARIA; PLASMODIUM FALCIPARUM; SCREENING; TANZANIA;

ANIMALS; ANTIMALARIALS; ARTEMISININS; DRUG RESISTANCE; HUMANS; PLASMODIUM FALCIPARUM; POLYMERASE CHAIN REACTION; SESQUITERPENES; TANZANIA;

EID: 33846600057     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/1475-2875-5-126     Document Type: Article

References (14)

1. The East African Network for Monitoring Antimalarial Treatment (EANMAT): The efficacy of antimalarial monotherapies, sulfadoxine-pyrimethamine and amodiaquine in East Africa: implication for sub-regional policy. Trop Med Int Health 2003, 8:860-867.
2. Talisuna AO, Bloland P, D'Alessandro U: History, dynamics, and public health importance of malaria parasite resistance. Clin Microbiol Rev 2004, 17:235-254.
3. World Health Organization 2006. Guidelines for malaria treatment [http://www.who.int/malaria/docs/TreatmentGuidelines2006.pdf]
4. Arrow J, Panosian CB, Gelband H, (Eds): Saving lives, buying time: Economics of malaria drugs in an age of resistance Washington DC, USA: National Academy Press; 2004.
5. Mugittu K, Ndejembi M, Malisa A, Lemnge M, Premji Z, Mwita A, Nkya W, Kataraihya J, Abdulla S, Beck HP, Mshinda H: Therapeutic efficacy of sulfadoxine-pyrimethamine and prevalence of resistance markers in Tanzania prior to revision of malaria treatment policy: Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase mutations in monitoring in vivo resistance. Am J Trop Med Hyg 2004, 71:696-702.
6. Duffy PE, Sibley CH: Are we losing artemisinin combination therapy already? Lancet 2005, 366:1960-1963.
7. Eckstein-Ludwig U, Webb RJ, Van Goethem ID, East JM, Lee AG, Kimura M, O'Neill PM, Bray PG, Ward SA, Krishna S: Artemisinins target the SERCA of Plasmodium falciparum. Nature 2003, 424:957-961.
8. Uhlemann AC, Cameron A, Eckstein-Ludwig U, Fischbarg J, Iserovich P, Zuniga FA, East M, Lee A, Brady L, Haynes RK, Krishna S: A single amino acid residue can determine the sensitivity of SERCAs to artemisinins. Nat Struct Mol Biol 2005, 12:628-629.
9. Jambou R, Legrand E, Niang M, Khim N, Lim P, Volney B, Ekala MT, Bouchier C, Esterre P, Fandeur T, Mercereau-Puijalon OS: Resistance of Plasmodium falciparum field isolates to in-vitro artemether and point mutations of the SERCA-type PfATPase6. Lancet 2005, 366:1960-1963.
10. Kachur SP, Black C, Abdulla S, Goodman C: Putting the genie back in the bottle? Availability and presentation of oral artemisinin compounds at retail pharmacies in urban Dar-es-Salaam. Malar J 2006, 5:25.
11. Falade C, Makanga M, Premji Z, Ortmann CE, Stockmeyer M, de Palacios PI: Efficacy and safety of artemether-lumefantrine (Coartem) tablets (six-dose regimen) in African infants and children with acute, uncomplicated falciparum malaria. Trans R Soc Trop Med Hyg 2005, 99:459-467.
12. Price RN, Cassar C, Brockman A, Duraisingh M, van Vugt M, White NJ, Nosten F, Krishna S: The pfmdr1 gene is associated with a multidrug-resistant phenotype in Plasmodium falciparum from the western border of Thailand. Antimicrob Agents Chemother 1999, 43(12):2943-9.
13. Duraisingh MT, Cowman AF: Contribution of the pfmdr1 gene to antimalarial drug-resistance. Acta Trop 2005, 94(3):181-90.
14. Afonso A, Hunt P, Cheesman S, Alves AC, Cunha CV, do Rosario V, Cravo P: Malaria parasites can develop stable resistance to artemisinin but lack mutations in candidate genes atp6 (encoding the sarcoplasmic and endoplasmic reticulum Ca2+ ATPase), tctp, mdr1, and cg10. Antimicrob Agents Chemother 2006, 50:480-489.